The legal dispute centers on a J&J study released earlier this month, which claimed Erleada achieved a 51% reduction in the risk of death for patients with metastatic castration-sensitive prostate cancer compared to Nubeqa. This specific finding applied to patients not undergoing concurrent chemotherapy with docetaxel. Bayer alleges these claims are deceptive because they do not stem from a controlled, head-to-head clinical trial.

Disputes Over Study Methodology

In its complaint, Bayer asserts that J&J’s analysis failed to adequately measure essential prognostic factors and baseline characteristics, such as non-cancer comorbidities. Bayer further highlights a significant statistical imbalance: the patient group treated with Erleada in the study was five times the size of the Nubeqa group. The German pharmaceutical giant maintains that these discrepancies invalidate J&J’s comparative conclusions.

Johnson & Johnson has signaled its intent to defend the study. In an official statement, the company said it stands by the "rigor and integrity" of its real-world, head-to-head analysis. The case represents a high-stakes clash over market share in the oncology sector, where both Janssen Biotech and Bayer are competing for dominance in treating advanced prostate cancer.